CGEM:NSD-Cullinan Oncology, Inc (USD)

COMMON STOCK | Other | NSD

Last Closing Price

USD 52.29

Change

+3.90 (+8.06)%

Market Cap

USD 2.18B

Volume

0.26M

Average Target Price

USD 48.00 (-8.20%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Cullinan Management, Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. Its lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. The company's preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell acute lymphoblastic leukemia; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. Cullinan Management, Inc. has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Management, Inc. was founded in 2016 and is headquartered in Cambridge, Massachusetts. Address: One Main Street, Cambridge, MA, United States, 02142

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-03-02 )

Largest Industry Peers for Other

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
LGCY Legacy Reserves Inc

N/A

USD61,525,874.67B 1.10 5.30
FTD FTD Companies, Inc

N/A

USD28,725,913.80B N/A N/A
KEYW The KeyW Holding Corporation

N/A

USD24,651,104.38B 166.80 24.48
SNHY Helios Technologies, Inc

N/A

USD17,848,852.22B 1,000,000.00 N/A
QTNA Quantenna Communications, Inc

N/A

USD8,997,243.52B 175.07 79.98
INSY INSYS Therapeutics, Inc

N/A

USD4,995,459.82B 115.90 N/A
CHKE Apex Global Brands Inc

N/A

USD384,202.91B 17.30 N/A
AMCN AirNet Technology Inc

N/A

USD308,457.30B 1.00 N/A
PDVW pdvWireless, Inc

N/A

USD95,944.74B N/A N/A
AIPT Predictive Oncology Inc

N/A

USD38,513.36B N/A N/A

ETFs Containing CGEM

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Other)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A 100% A+ 100% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A 100% A+ 100% A+
Trailing 12 Months  
Capital Gain N/A 100% A+ 100% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A 100% A+ 100% A+
Trailing 5 Years  
Capital Gain 74,600.00% 89% B+ 100% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 74,600.00% 89% B+ 100% A+
Average Annual (5 Year Horizon)  
Capital Gain 6,061.15% 96% A 100% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 6,061.15% 96% A 100% A+
Risk Return Profile  
Volatility (Standard Deviation) 33,816.54% 4% F N/A N/A
Risk Adjusted Return 17.92% 42% F 45% F
Market Capitalization 2.18B 79% C+ 74% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Other)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 9.30 17% F 22% F
Price / Cash Flow Ratio -104.45 92% A- 94% A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital 72.51% 97% A+ 98% A+
Return on Assets N/A N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 2.40 47% F 48% F
Short Percent 2.33% 86% B 59% F
Beta 0.90 34% F 67% D+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector